» Articles » PMID: 24304332

Long-term Multimodal Therapy (verapamil Associated with Propolis, Blueberry, Vitamin E and Local Diclofenac) on Patients with Peyronie's Disease (chronic Inflammation of the Tunica Albuginea). Results of a Controlled Study

Overview
Date 2013 Dec 6
PMID 24304332
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: to demonstrate the possible effectiveness of a long-term multimodal medical therapy in patients with Peyronie's disease (PD) we carried out a controlled study on 82 patients diagnosed with PD, whereas in the scientific literature the conservative treatment of this disease is much discussed.

Methods: 82 patients (mean age=53.6±10.1 years-range 23-68) diagnosed with PD were selected for this study. Of these 41 patients (group A) were treated for 18 months as follows: Verapamil penile injections (12 total injections for six months and subsequently every month for twelve months: total 24 injections) + Iontophoresis with Verapamil/daily + blueberries 160mg/daily + propolis 600mg/daily + Vitamin E 600mg/daily + topical Diclofenac/daily. The other 41 patients spontaneously decided not to receive treatment for several motives and then were introduced as a control group B. All patients were controlled at 6- and 18-month follow up with the same diagnostic tests completed before the therapy (penile ultrasound, photograph documentation, pain scale etc.).

Results: In group A, after treatment of 6 and 18 months, the change in plaque volume consisted in volume reduction= - 47.6% and -73.6% respectively, while in group B, the change consisted of an increase in plaque volume= +55.7% and +118.7% respectively (p=0.000). In group A, after treatment of 6 and 18 months, improvement of curvature occurred in 76.3% and 81.5% of the cases respectively, while in group B it occurred in 2.7% and 8.1%, respectively (p<0.0001).

Conclusion: Our results showed that a long-term multimodal medical therapy (Verapamil associated with Antioxidants and local Diclofenac) is statistically effective to treat PD patients, if we consider that lower therapeutic outcomes were achieved after 6 months treatment (medium-term treatment). Furthermore, this study confirms that the best treatment modality for PD is a combination therapy.

Citing Articles

Oxidative Mechanism of Peyronie's Disease and Effectiveness of Pentoxifylline in the Therapeutic Management: A Narrative Review.

Paulis G, Paulis A Antioxidants (Basel). 2025; 14(2).

PMID: 40002394 PMC: 11851550. DOI: 10.3390/antiox14020208.


Acute Phase Peyronie's Disease: Where Do We Stand?.

Douroumis K, Kotrotsios K, Katsikatsos P, Moulavasilis N, Fragkiadis E, Mitropoulos D Cureus. 2024; 16(8):e67054.

PMID: 39286663 PMC: 11403542. DOI: 10.7759/cureus.67054.


Measurement of Oxidative Stress Index (OSI) in Penile Corpora Cavernosa and Peripheral Blood of Peyronie's Disease Patients: A Report of 49 Cases.

Paulis G, Paulis A, De Giorgio G, Quattrocchi S Metabolites. 2024; 14(1).

PMID: 38248858 PMC: 10821449. DOI: 10.3390/metabo14010055.


Non-surgical therapies for Peyronie's disease.

Rosenberg J, Ergun O, Hwang E, Risk M, Jung J, Edwards M Cochrane Database Syst Rev. 2023; 7:CD012206.

PMID: 37490423 PMC: 10351344. DOI: 10.1002/14651858.CD012206.pub2.


Role of Oxidative Stress in Peyronie's Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants.

Paulis G, De Giorgio G, Paulis L Int J Mol Sci. 2022; 23(24).

PMID: 36555611 PMC: 9781573. DOI: 10.3390/ijms232415969.